Stocktwits on MSN
CAPR stock in focus: Ex-exec eyed for FDA role says drug approvals are not 'best-in-class' signals
Hemmati is reportedly being considered for a leadership role at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. ・The regulatory spotlight has intensified ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Clene Inc. CLNN shares are up 6.68% on Monday as the company is filing for accelerated approval of its ALS treatment ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for ...
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply ...
Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
Corcept Therapeutics Incorporated is a Strong Buy after early FDA approval of Lyforli for PROC, with upside from EU decisions ...
Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results